Clinical Updates

A regimen that integrates treatments for high blood pressure (hypertension) and depression is better than the usual care for improving… »   

Come next year, doctors may start to see a problem they’ve yet to experience—a pen shortage.

New guidelines… »   

U.S. regulators will change the way they tell drugmakers that their medicines are not ready to be approved, the Food… »   

Prolonged use of Fosamax, also referred to by the generic name bisphosphonate alendronate, may increase the risk of fractures of… »   

Dementia is one of the major challenges of the 21st century due to the enormous burden these disorders impose on… »   

Medivation Inc said on Monday its experimental drug, Dimebon, was shown in a mid-stage trial to significantly improve cognitive function… »   

Research by a Davidson College neuroscientist and students demonstrates that the benefits of regular exercise include a lowered tendency to… »   

Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor… »   

Pain-killing medicine is often withheld during painful and stressful procedures performed on critically ill newborn infants in intensive care units,… »   

Bone growth products made by Medtronic Inc and Stryker Corp have been linked to life-threatening complications when used without approval… »   

General anesthesia during surgery may increase patients’ pain after they regain consciousness, U.S. researchers said on Monday.

They… »   

U.S. drug regulators are close to allowing doctors to electronically prescribe potentially addictive medications like painkillers, rather than requiring written… »   

Medicine has moved a little bit closer to the era of tailor-made treatments, based on the unique genetic profiles of… »   

Johnson & Johnson’s experimental drug ustekinumab should be approved for treating adults with moderate or severe psoriasis, a U.S. advisory… »   

Britain’s Department of Health has picked GlaxoSmithKline’s cervical cancer vaccine Cervarix over Merck’s Gardasil for its immunisation programme, Glaxo said… »